Learn more about the research of Mayo Clinic's Gene Editing and Cellular Engineering Laboratory led by David (Chun-Wei) D.

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making immediate treatment essential. While chemotherapy and targeted drugs have ...

Researchers have developed a peptide that targets a previously ‘undruggable’ protein implicated in more than 75% of human cancers and found that it slowed the proliferation of brain cancer ...

FAST kinase domain-containing protein 5 (FASTKD5) is a mitochondrial protein that is needed for processing mRNA in the primary mitochondrial transcript. Several mutations have been found in other ...

Now, scientists think they can throw a wrench into the fabrication of a key growth-related protein, MYC, that escalates wildly in 70% of all cancers.

They found that a protein called RBM10 can partner with other proteins to stop c-Myc activity, which is a tumor-stimulating protein that causes lung cancers.

A gene called MYC is implicated in the majority of cancers, but unfortunately it’s often considered “undruggable.” In a new study scientists have developed a molecule that chops up the RNA ...

Hollow spheres made of MYC proteins open new doors in cancer research. Würzburg scientists have discovered them and report about this breakthrough in the journal "Nature".

In mammals three proteins, c-Myc, N-Myc, and L-Myc have reasonable structural resemblance and are encoded by three different genes, and their over expression reportedly leads to tumor induction.